Malika Hale

Ms. Malika Hale

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2015 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BSBlythe D. Sather
Blythe D. Sather
GIGuillermo S. Romano Ibarra
Guillermo S. Romano Ibarra
KSKaren Sommer
Karen Sommer
GCGabrielle Curinga
Gabrielle Curinga
MHMalika Hale
Malika Hale
DRDavid J. Rawlings
David J. Rawlings
Therapeutic coding sequences can be targeted to the CCR5 locus of primary human T cells with high efficiency by using megaTAL nuclease and an AAV donor template.

1 March 2017 in Molecular Therapy
Verified
Journal Article
Open access
MHMalika Hale
Malika Hale
TMTaylor Mesojednik
Taylor Mesojednik
GIGuillermo S. Romano Ibarra
Guillermo S. Romano Ibarra
JSJaya Sahni
Jaya Sahni
ABAlison Bernard
Alison Bernard
TWThor A. Wagner
Thor A. Wagner
The treatment or cure of HIV infection by cell and gene therapy has been a goal for decades. Recent advances in both gene editing and chimeric antigen receptor (CAR) technology have created new therapeutic possibilities for a variety of diseases. Broadly neutralizing monoclonal antibodies (bNAbs) with specificity for the HIV envelope glycoprotein provide a promising means of targeting HIV-infected cells. Here we show that primary human T cells engineered to express anti-HIV CARs based on bNAbs (HIVCAR) show specific activation and killing of HIV-infected versus uninfected cells in the absence of HIV replication. We also show that homology-directed recombination of the HIVCAR gene expression cassette into the CCR5 locus enhances suppression of replicating virus compared with HIVCAR expression alone. This work demonstrates that HIV immunotherapy utilizing potent bNAb-based single-chain variable fragments fused to second-generation CAR signaling domains, delivered directly into the CCR5 locus of T cells by homology-directed gene editing, is feasible and effective. This strategy has the potential to target HIV-infected cells in HIV-infected individuals, which might help in the effort to cure HIV.

1 February 2018 in Molecular Therapy
Verified
Journal Article
Open access
KHKing L. Hung
King L. Hung
IMIana Meitlis
Iana Meitlis
MHMalika Hale
Malika Hale
CCChun-Yu Chen
Chun-Yu Chen
SSSwati Singh
Swati Singh
RJRichard G. James
Richard G. James
The ability to engineer primary human B cells to differentiate into long-lived plasma cells and secrete a de novo protein may allow the creation of novel plasma cell therapies for protein deficiency diseases and other clinical applications. We initially developed methods for efficient genome editing of primary B cells isolated from peripheral blood. By delivering CRISPR/CRISPR-associated protein 9 (Cas9) ribonucleoprotein (RNP) complexes under conditions of rapid B cell expansion, we achieved site-specific gene disruption at multiple loci in primary human B cells (with editing rates of up to 94%). We used this method to alter ex vivo plasma cell differentiation by disrupting developmental regulatory genes. Next, we co-delivered RNPs with either a single-stranded DNA oligonucleotide or adeno-associated viruses containing homologous repair templates. Using either delivery method, we achieved targeted sequence integration at high efficiency (up to 40%) via homology-directed repair. This method enabled us to engineer plasma cells to secrete factor IX (FIX) or B cell activating factor (BAFF) at high levels. Finally, we show that introduction of BAFF into plasma cells promotes their engraftment into immunodeficient mice. Our results highlight the utility of genome editing in studying human B cell biology and demonstrate a novel strategy for modifying human plasma cells to secrete therapeutic proteins.

3 June 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
YHYuchi Honaker
Yuchi Honaker
NHNicholas Hubbard
Nicholas Hubbard
YXYufei Xiang
Yufei Xiang
LFLogan Fisher
Logan Fisher
DHDavid Hagin
David Hagin
DRDavid J. Rawlings
David J. Rawlings
Gene editing to insert a strong promoter upstream of endogenous FOXP3 conferred T reg -like properties and functions to primary human CD4 + T cells.

13 March 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MHMalika Hale
Malika Hale
FIFarah Itani
Farah Itani
CBClaire M Buchta
Claire M Buchta
GWGal Wald
Gal Wald
MBMegan Bing
Megan Bing
Lyse A. NorianLyse A. Norian
Lyse A. Norian
Obesity is one of the leading risk factors for developing renal cell carcinoma, an immunogenic tumor that is treated clinically with immunostimulatory therapies. Currently, however, the mechanisms linking obesity with renal cancer incidence are unclear. Using a model of diet-induced obesity, we found that obese BALB/c mice with orthotopic renal tumors had increased total frequencies of myeloid-derived suppressor cells (MDSC) in renal tumors and spleens by d14 post-tumor challenge, relative to lean counterparts. Renal tumors from obese mice had elevated concentrations of the known myeloid cell chemoattractant CCL2, which was produced locally by increased percentages of dendritic cells, macrophages, B cells, and CD45- cells in tumors. MDSC expression of the CCL2 receptor, CCR2, was unaltered by obesity but greater percentages of CCR2+ MDSCs were present in renal tumors from obese mice. Of note, the intracellular arginase levels and per-cell suppressive capacities of tumor-infiltrating and splenic MDSCs were unchanged in obese mice relative to lean controls. Thus, our findings suggest that obesity promotes renal tumor progression via development of a robust immunosuppressive environment that is characterized by heightened local and systemic MDSC prevalence. Targeted intervention of the CCL2/CCR2 pathway may facilitate immune-mediated renal tumor clearance in the obese.

1 March 2017 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
MHMalika Hale
Malika Hale
BLBaeckseung Lee
Baeckseung Lee
YHYuchi Honaker
Yuchi Honaker
WLWai-Hang Leung
Wai-Hang Leung
AGAlexandra E. Grier
Alexandra E. Grier
DRDavid J. Rawlings
David J. Rawlings
Gene editing by homology-directed recombination (HDR) can be used to couple delivery of a therapeutic gene cassette with targeted genomic modifications to generate engineered human T cells with clinically useful profiles. Here, we explore the functionality of therapeutic cassettes delivered by these means and test the flexibility of this approach to clinically relevant alleles. Because CCR5-negative T cells are resistant to HIV-1 infection, CCR5-negative anti-CD19 chimeric antigen receptor (CAR) T cells could be used to treat patients with HIV-associated B cell malignancies. We show that targeted delivery of an anti-CD19 CAR cassette to the CCR5 locus using a recombinant AAV homology template and an engineered megaTAL nuclease results in T cells that are functionally equivalent, in both in vitro and in vivo tumor models, to CAR T cells generated by random integration using lentiviral delivery. With the goal of developing off-the-shelf CAR T cell therapies, we next targeted CARs to the T cell receptor alpha constant (TRAC) locus by HDR, producing TCR-negative anti-CD19 CAR and anti-B cell maturation antigen (BCMA) CAR T cells. These novel cell products exhibited in vitro cytolytic activity against both tumor cell lines and primary cell targets. Our combined results indicate that high-efficiency HDR delivery of therapeutic genes may provide a flexible and robust method that can extend the clinical utility of cell therapeutics.